But with only about 12,000 dermatologists in the U.S., some patients may have trouble finding a provider. Telehealth ...

Telehealth personalized care company Hims & Hers shuttered a central part of its dermatology offering, skincare brand Apostrophe, to "simplify" its dermatology offerings and operations ...

To make the world smarter, happier, and richer. Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches ...

Below is Validea's guru fundamental report for HIMS & HERS HEALTH INC (HIMS). Of the 22 guru strategies we follow, HIMS rates highest using our Small-Cap Growth Investor model based on the ...

Hims & Hers Health (HIMS) has disclosed plans to shut down Apostrophe, its acne treatment business. This change is part of Hims & Hers’ plan to combine all its dermatology services into one main ...

Hims & Hers generated $1.5 billion in revenue in 2024, reflecting a 69% year-over-year increase. See why I rate HIMS stock a strong buy.

Shares of HIMS stock opened at $36.01 on Thursday. Hims & Hers Health has a 12-month low of $11.20 and a 12-month high of $72.98. The firm has a market capitalization of $8.00 billion, a price-to ...

NYSE HIMS opened at $36.01 on Thursday. The stock has a market cap of $8.00 billion, a P/E ratio of 81.85 and a beta of 1.37. The company’s 50-day simple moving average is $37.64 and its 200 day ...

Hims & Hers is shutting down the dermatology business it acquired in 2021, BI has learned. It said it's closing the skincare site Apostrophe to centralize its teledermatology offerings. Hims ...

(Reuters) -Hims & Hers Health would discontinue Apostrophe, its personalized acne treatments dermatology business, the company said on Friday. Apostrophe is being shut down to "simplify its (company's ...